GetTopicDetailResponse(id=b5c01e78457, topicName=Trebananib, introduction=Trebananib, content=null, image=null, comments=4, allHits=1131, url=https://h5.medsci.cn/topic?id=17784, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=62043, tagList=[TagDto(tagId=62043, tagName=Trebananib)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1987467, encodeId=f1ef198e467d7, content=<a href='/topic/show?id=b5c01e78457' target=_blank style='color:#2F92EE;'>#Trebananib#</a>, objectTitle=Lancet Oncol：Trebananib聯(lián)合紫杉醇和卡鉑作為一線療法用于晚期卵巢癌患者的療效和安全性, objectType=article, longId=166883, objectId=967c166883ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=967c166883ab, replyNumber=0, likeNumber=99, createdTime=2020-03-28, rootId=0, userName=gao_jian4217, userId=c66088, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=967c166883ab, moduleTitle=Lancet Oncol：Trebananib聯(lián)合紫杉醇和卡鉑作為一線療法用于晚期卵巢癌患者的療效和安全性, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=967c166883ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987465, encodeId=e938198e46513, content=<a href='/topic/show?id=b5c01e78457' target=_blank style='color:#2F92EE;'>#Trebananib#</a>, objectTitle=CLIN CANCER RES：Trebananib用于治療兒童復發(fā)實體腫瘤及原發(fā)神經系統(tǒng)腫瘤的Ⅰ期臨床試驗結果, objectType=article, longId=118031, objectId=498d118031bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=498d118031bc, replyNumber=0, likeNumber=101, createdTime=2018-02-21, rootId=0, userName=gao_jian4217, userId=c66088, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=498d118031bc, moduleTitle=CLIN CANCER RES：Trebananib用于治療兒童復發(fā)實體腫瘤及原發(fā)神經系統(tǒng)腫瘤的Ⅰ期臨床試驗結果, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=498d118031bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987466, encodeId=d898198e46602, content=<a href='/topic/show?id=b5c01e78457' target=_blank style='color:#2F92EE;'>#Trebananib#</a>, objectTitle=EUR J Cancer：聚乙二醇化脂質體多柔比星聯(lián)合trebananib或安慰劑治療卵巢癌的隨機雙盲III期臨床試驗, objectType=article, longId=125219, objectId=0ec912521937, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ec912521937, replyNumber=0, likeNumber=77, createdTime=2018-11-07, rootId=0, userName=gao_jian4217, userId=c66088, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ec912521937, moduleTitle=EUR J Cancer：聚乙二醇化脂質體多柔比星聯(lián)合trebananib或安慰劑治療卵巢癌的隨機雙盲III期臨床試驗, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=0ec912521937)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987464, encodeId=56f8198e4644f, content=<a href='/topic/show?id=b5c01e78457' target=_blank style='color:#2F92EE;'>#Trebananib#</a>, objectTitle=Nat Rev Drug Discov：血管生成素抑制劑 trebananib三期臨床失敗, objectType=article, longId=43656, objectId=672943656a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=672943656a5, replyNumber=0, likeNumber=78, createdTime=2015-03-07, rootId=0, userName=gao_jian4217, userId=c66088, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=672943656a5, moduleTitle=Nat Rev Drug Discov：血管生成素抑制劑 trebananib三期臨床失敗, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=672943656a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
